Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241459 | 0.89 | ACHE (0.41) | GRIN2BSIGMAR1ACHESCN1ASCN8A | |
| SCHEMBL4237325 | 0.85 | SIGMAR1 (0.42) | GRIN2BSIGMAR1SCN1ASCN8AMEN1 | |
| SCHEMBL4244914 | 0.84 | MEN1 (0.42) | SIGMAR1ACHES1PR1MEN1KMT2A | |
| SCHEMBL4250529 | 0.84 | MEN1 (0.40) | SIGMAR1ACHES1PR1MEN1KMT2A | |
| SCHEMBL4244829 | 0.81 | SIGMAR1 (0.41) | GRIN2BSIGMAR1ACHECHRM2MEN1 | |
| SCHEMBL4240896 | 0.80 | SIGMAR1 (0.40) | GRIN2BSIGMAR1ACHESCN1ASCN8A | |
| SCHEMBL4238217 | 0.78 | HTT (0.45) | SIGMAR1ACHEMEN1KMT2AKDM4E | |
| SCHEMBL4248187 | 0.76 | CCR5 (0.39) | ACHEKDM4E | |
| SCHEMBL4237283 | 0.74 | SIGMAR1 (0.42) | SIGMAR1S1PR1MEN1KMT2A | |
| SCHEMBL4248026 | 0.73 | PTGIR (0.57) | PTGIRPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | GRIN2B 421/4885SIGMAR1 317/4885ACHE 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.